1. bookVolume 58 (2020): Edition 3 (September 2020)
Détails du magazine
License
Format
Magazine
eISSN
2501-062X
Première parution
30 Mar 2015
Périodicité
4 fois par an
Langues
Anglais
Accès libre

Real-life outcomes of unselected acute promyelocytic leukemia patients: a single-center 14-year experience

Publié en ligne: 10 Aug 2020
Volume & Edition: Volume 58 (2020) - Edition 3 (September 2020)
Pages: 138 - 145
Reçu: 10 Feb 2020
Détails du magazine
License
Format
Magazine
eISSN
2501-062X
Première parution
30 Mar 2015
Périodicité
4 fois par an
Langues
Anglais

1. DE BRAEKELEER E., DOUET-GUILBERT N., and DE BRAEKELEER M., RARA fusion genes in acute promyelocytic leukemia: a review. Expert Rev Hematol, 2014. 7(3): p. 347–357.10.1586/17474086.2014.903794Search in Google Scholar

2. GIRI S., PATHAK R., ARYAL M.R., KARMACHARYA P., and BHATT V.R., Second primary malignancy in acute promyelocytic leukemia: a Surveillance, Epidemiology and End Results database study. Future Oncol, 2017. 13(17): p. 1455–1457.10.2217/fon-2017-0077Search in Google Scholar

3. THULER L.C.S. and POMBO-DE-OLIVEIRA M.S., Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012. Ann Hematol, 2017. 96(3): p. 355–362.10.1007/s00277-016-2846-0Search in Google Scholar

4. DINMOHAMED A.G. and VISSER O., Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study. Stem Cell Investig, 2019. 6: p. 37–37.10.21037/sci.2019.10.03Search in Google Scholar

5. KANTARJIAN H.M., KEATING M.J., WALTERS R.S., ESTEY E.H., MCCREDIE K.B., SMITH T.L., et al., Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med, 1986. 80(5): p. 789–97.10.1016/0002-9343(86)90617-0Search in Google Scholar

6. TALLMAN M.S., ANDERSEN J.W., SCHIFFER C.A., APPELBAUM F.R., FEUSNER J.H., OGDEN A., et al., All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med, 1997. 337(15): p. 1021–8.10.1056/NEJM1997100933715019321529Search in Google Scholar

7. FENAUX P., CASTAIGNE S., DOMBRET H., ARCHIMBAUD E., DUARTE M., MOREL P., et al., All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood, 1992. 80(9): p. 2176–81.10.1182/blood.V80.9.2176.2176Search in Google Scholar

8. LO-COCO F., AVVISATI G., VIGNETTI M., THIEDE C., ORLANDO S.M., IACOBELLI S., et al., Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. N Engl J Med, 2013. 369(2): p. 111–121.10.1056/NEJMoa130087423841729Search in Google Scholar

9. SANZ M.A., MONTESINOS P., RAYÓN C., HOLOWIECKA A., DE LA SERNA J., MILONE G., et al., Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 2010. 115(25): p. 5137–5146.10.1182/blood-2010-01-26600720393132Search in Google Scholar

10. MICOL J.B., RAFFOUX E., BOISSEL N., LENGLINE E., CANET E., DANIEL M.T., et al., Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. Eur J Cancer, 2014. 50(6): p. 1159–68.10.1016/j.ejca.2013.11.02324440088Search in Google Scholar

11. LEHMANN S., RAVN A., CARLSSON L., ANTUNOVIC P., DENEBERG S., MÖLLGÅRD L., et al., Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 2011. 25(7): p. 1128–1134.10.1038/leu.2011.7821502956Search in Google Scholar

12. PAGONI M., GAROFALAKI M., PANITSAS F., MANOLA K., PSARRA K., ECONOMOPOULOS P., et al., Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis, 2011. 3(1): p. e2011053–e2011053.10.4084/mjhid.2011.053Search in Google Scholar

13. KARIM F., SHAIKH U., ADIL S.N., and KHURSHID M., Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre. Singapore Med J, 2014. 55(8): p. 443–447.10.11622/smedj.2014105429409625189308Search in Google Scholar

14. SILVA W.F.D., JR., ROSA L.I.D., MARQUEZ G.L., BASSOLLI L., TUCUNDUVA L., SILVEIRA D.R.A., et al., Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil – Early Deaths Are Still a Problem. Clin Lymphoma Myeloma Leuk, 2019. 19(2): p. e116–e122.10.1016/j.clml.2018.11.00430509780Search in Google Scholar

15. PAULSON K., SEREBRIN A., LAMBERT P., BERGERON J., EVERETT J., KEW A., et al., Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol, 2014. 166(5): p. 660–666.10.1111/bjh.1293124780059Search in Google Scholar

16. PARK J.H., QIAO B., PANAGEAS K.S., SCHYMURA M.J., JURCIC J.G., ROSENBLAT T.L., et al., Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 2011. 118(5): p. 1248–1254.10.1182/blood-2011-04-346437379094621653939Search in Google Scholar

17. MCCLELLAN J.S., KOHRT H.E., COUTRE S., GOTLIB J.R., MAJETI R., ALIZADEH A.A., et al., Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica, 2012. 97(1): p. 133.10.3324/haematol.2011.046490324894221993679Search in Google Scholar

18. LO-COCO F., AVVISATI G., VIGNETTI M., BRECCIA M., GALLO E., RAMBALDI A., et al., Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood, 2010. 116(17): p. 3171–9.10.1182/blood-2010-03-27619620644121Search in Google Scholar

19. SANZ M.A., LO COCO F., MARTÍN G., AVVISATI G., RAYÓN C., BARBUI T., et al., Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood, 2000. 96(4): p. 1247–1253.Search in Google Scholar

20. CHEN Y., KANTARJIAN H., WANG H., CORTES J., and RAVANDI F., Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer, 2012. 118(23): p. 5811–8.10.1002/cncr.27623418024622707337Search in Google Scholar

21. SANZ M.A., MONTESINOS P., VELLENGA E., RAYON C., DE LA SERNA J., PARODY R., et al., Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, 2008. 112(8): p. 3130–4.10.1182/blood-2008-05-15963218664623Search in Google Scholar

22. ADES L., SANZ M.A., CHEVRET S., MONTESINOS P., CHEVALLIER P., RAFFOUX E., et al., Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood, 2008. 111(3): p. 1078–84.10.1182/blood-2007-07-099978Search in Google Scholar

23. KELAIDI C., CHEVRET S., DE BOTTON S., RAFFOUX E., GUERCI A., THOMAS X., et al., Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol, 2009. 27(16): p. 2668–76.10.1200/JCO.2008.18.4119Search in Google Scholar

24. SOBAS M., CZYŻ A., MONTESINOS P., ARMATYS A., HELBIG G., HOŁOWIECKA A., et al., Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience. Clin Lymphoma Myeloma Leuk, 2019.10.1016/j.clml.2019.09.616Search in Google Scholar

25. JÁCOMO R.H., MELO R.A.M., SOUTO F.R., DE MATTOS É.R., DE OLIVEIRA C.T., FAGUNDES E.M., et al., Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica, 2007. 92(10): p. 1431.10.3324/haematol.10874Search in Google Scholar

26. SANZ M.A., MONTESINOS P., RAYON C., HOLOWIECKA A., DE LA SERNA J., MILONE G., et al., Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 2010. 115(25): p. 5137–46.10.1182/blood-2010-01-266007Search in Google Scholar

27. DE LA SERNA J., MONTESINOS P., VELLENGA E., RAYON C., PARODY R., LEON A., et al., Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 2008. 111(7): p. 3395–402.10.1182/blood-2007-07-100669Search in Google Scholar

28. SANZ M.A. and MONTESINOS P., Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res, 2010. 125: p. S51–S54.10.1016/S0049-3848(10)70013-XSearch in Google Scholar

29. LEHMANN S., RAVN A., CARLSSON L., ANTUNOVIC P., DENEBERG S., MOLLGARD L., et al., Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 2011. 25(7): p. 1128–34.10.1038/leu.2011.7821502956Search in Google Scholar

30. PARK J.H., QIAO B., PANAGEAS K.S., SCHYMURA M.J., JURCIC J.G., ROSENBLAT T.L., et al., Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood, 2011. 118(5): p. 1248–54.10.1182/blood-2011-04-346437379094621653939Search in Google Scholar

31. BURNETT A.K., HILLS R.K., GRIMWADE D., JOVANOVIC J.V., CRAIG J., MCMULLIN M.F., et al., Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia, 2013. 27(4): p. 843–851.10.1038/leu.2012.36023222369Search in Google Scholar

32. LENGFELDER E., GORLICH D., NOWAK D., SPIEKERMANN K., HAFERLACH C., KRUG U., et al., Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines. Eur J Haematol, 2018. 100(2): p. 154–162.10.1111/ejh.1299429114972Search in Google Scholar

33. TALLMAN M.S., ANDERSEN J.W., SCHIFFER C.A., APPELBAUM F.R., FEUSNER J.H., WOODS W.G., et al., All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood, 2002. 100(13): p. 4298–302.10.1182/blood-2002-02-063212393590Search in Google Scholar

34. NØRGAARD J.M., FRIIS L.S., KRISTENSEN J.S., SEVERINSEN M.T., MØLLE I., MARCHER C.W., et al., Addressing the room for improvement in management of acute promyelocytic leukemia. European Journal of Haematology, 2019. 102(6): p. 479–485.10.1111/ejh.1322930887583Search in Google Scholar

35. REGO E.M., KIM H.T., RUIZ-ARGUELLES G.J., UNDURRAGA M.S., URIARTE MDEL R., JACOMO R.H., et al., Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, 2013. 121(11): p. 1935–43.10.1182/blood-2012-08-44991823319575Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo